Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations

Medicine, Molecular Biology, Oncology +15

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Purva Bali, Michael Pranpat, James E. Bradner et al. · Journal of Biological Chemistry · 2005 · 749 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis

Carlo Gambacorti‐Passerini, Philipp le Coutre, Luca Mologni et al. · Blood Cells Molecules and Diseases · 1997 · 319 citations

Life Sciences, Cancer Biology, Oncology +12

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

Ramadevi Nimmanapalli, Lianne Fuino, Purva Bali et al. · PubMed · 2003 · 280 citations

Life Sciences, Oncology, Pharmacology +17

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl–positive human acute leukemia cells

Ramadevi Nimmanapalli, Lianne Fuino, Corinne Stobaugh et al. · Blood · 2003 · 221 citations · Full text

Life Sciences, Oncology, Pharmacology +12